Key clinical point: The BET inhibitor CPI-0610, given alone or in combination with ruxolitinib, has demonstrated activity in a phase 2 trial of patients with relapsed/refractory myelofibrosis.
Major finding: Of 9 evaluable patients who received CPI-0610 monotherapy, 4 had a 50% or greater improvement in total symptom score, as did 12 of 27 evaluable patients who received CPI-0610 and ruxolitinib.
Study details: A phase 2 trial of 90 patients, 36 who received monotherapy and 54 who received the combination.
Disclosures: The trial is funded by Constellation Pharmaceuticals in collaboration with the Leukemia & Lymphoma Society. Dr. Mascarenhas reported relationships with Incyte, Janssen, CTI Biopharma, Novartis, Roche, Merck, Celgene, Promedior, Merus, and PharmaEssentia.
Mascarenhas J et al. ASH 2019, Abstract 670.